Mitogenic activity of zeranol in human breast cancer cells is enhanced by leptin and suppressed by gossypol

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4621-4628

  Xu, Pingping ^a,b   Ye, Weiping ^a   Jen, Robert ^c   Lin, Shu Hong ^a   Kuo, Hieh Ti ^a   Lin, Young C ^a,d  

^a OHIO STATE UNIVERSITY   (United States)

^b Jinhua College of Profession and Technology   (China)

^c XAVIER UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

( ) gossypol; Breast cancer; Leptin; Zeranol

Indexed keywords

GOSSYPOL; RECOMBINANT LEPTIN; ZERANOL;

ARTICLE; BREAST CANCER; BREAST CELL; CANCER CELL; CELL GROWTH; CELL STRAIN MCF 7; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG EXPOSURE; HUMAN; HUMAN CELL; MITOGENESIS; PRIORITY JOURNAL;

ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; DRUG SYNERGISM; GOSSYPOL; HUMANS; LEPTIN; RECOMBINANT PROTEINS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; ZERANOL;

EID: 75149139441     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Lorincz AM and Sukumar S: Molecular links between obesity and breast cancer. Endocr Relat Cancer 13(2): 279-292, 2006.
2. Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17): 1625-1638, 2003.
3. De Waard F, Baanders-Vanhalewijn EA and Huizinga J: The bimodal age distribution of patients with mammary carcinoma; evidence for the existence of 2 types of human breast cancer. Cancer 17: 141-151, 1964.
4. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L and Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 372(6505): 425-432, 1994.
5. Rosen ED and Spiegelman BM: Adipocytes as regulators of energy balance and glucose homeostasis. Nature 444(7121): 847-853, 2006.
6. Calle EE and Thun MJ: Obesity and cancer. Oncogene 23(38): 6365-6378, 2004.
7. Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, Gourmelen M, Dina C, Chambaz J, Lacorte JM, Basdevant A, Bougneres P, Lebouc Y, Froguel P and Guy-Grand B: A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392(6674): 398-401, 1998.
8. Buschemeyer WC 3rd and Freedland SJ: Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 52(2):331-343, 2007.
9. Mistry T, Digby JE, Desai KM and Randeva HS: Obesity and prostate cancer: a role for adipokines. Eur Urol 52(1): 46-53, 2007.
10. Caldefie-Chezet F, Damez M, de Latour M, Konska G, Mishellani F, Fusillier C, Guerry M, Penault-Llorca F, Guillot J and Vasson MP: Leptin: a proliferative factor for breast cancer? Study on human ductal carcinoma. Biochem Biophys Res Commun 334(3): 737-741, 2005.
11. Rose DP, Komninou D and Stephenson GD: Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 5(3): 153-165, 2004.
12. Ishikawa M, Kitayama J and Nagawa H: Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 10(13): 4325-4331, 2004.
13. Laud K, Gourdou I, Pessemesse L, Peyrat JP and Djiane J: Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line. Mo1 Cell Endocrinol 188(1-2): 219-226, 2002.
14. Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-Koda L, Golaszewska J, Russo A, Sulkowski S and Surmacz E: Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res 12(5): 1447-1453, 2006.
15. Garofalo C and Surmacz E: Leptin and cancer. J Cell Physiol 207(1): 12-22, 2006.
16. Shida D, Kitayama J, Mori K, Watanabe T and Nagawa H: Transactivation of epidermal growth factor receptor is involved in leptin-induced activation of Janus-activated kinase 2 and extracellular signal-regulated kinase 1/2 in human gastric cancer cells. Cancer Res 65(20): 9159-9163, 2005.
17. Somasundar P, Riggs D, Jackson B, Vona-Davis L and McFadden DW: Leptin stimulates esophageal adenocarcinoma growth by nonapoptotic mechanisms. Am J Surg 186(5): 575-578, 2003.
18. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D and Anania FA: Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67(6): 2497-2507, 2007.
19. Larsson SC and WoIk A: Obesity and the risk of gallbladder cancer: a meta-analysis. Br J Cancer 96(9): 1457-1461, 2007.
20. Fava G, Alpini G, Rychlicki C, Saccomanno S, DeMorrow S, Trozzi L, Candelaresi C, Venter J, Di Sario A, Marzioni M, Bearzi I, Glaser S, Alvaro D, Marucci L, Francis H, Svegliati-Baroni G and Benedetti A: Leptin enhances cholangiocarcinoma cell growth. Cancer Res 68(16): 6752-6761, 2008.
21. Saxena NK, Vertino PM, Anania FA and Sharma D: leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN Dl promoter via activation of Stat3. J Biol Chem 282(18): 13316-13325, 2007.
22. Frankenberry KA, Skinner H, Somasundar P, McFadden DW and Vona-Davis LC: Leptin receptor expression and cell signaling in breast cancer. Int J Oncol 28(4): 985-993, 2006.
23. Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML and Ando S: Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem 278(31): 28668-28676, 2003.
24. Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, Rago V, Montanaro D, Maggiolini M, Panno ML and Ando S: Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem 279(19):19908-19915, 2004.
25. Yin N, Wang D, Zhang H, Yi X, Sun X, Shi B, Wu H, Wu G, Wang X and Shang Y: Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res 64(16): 5870-5875, 2004.
26. Garofalo C, Sisci D and Surmacz E: Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells. Clin Cancer Res 10(19): 6466-6475, 2004.
27. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, Leneveu MC, Pecquery R and Giudicelli Y: Leptin mediates a proliferative response in human MCF-7 breast cancer cells. Biochem Biophys Res Commun 293(1): 622-628, 2002.
28. Goodwin PJ, Ennis M, Fantus IG, Pritchard KI, Trudeau ME, Koo J and Hood N: Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol 23(25): 6037-6042, 2005.
29. WAF1/CIP1. Breast Cancer Res Treat 98(2): 121-132, 2006.
30. Hu X, Juneja SC, Maihle NJ and Cleary MP: Leptin - a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst 94(22): 1704-1711, 2002.
31. Thorn SR, Meyer MJ, Van Amburgh ME and Boisclair YR: Effect of estrogen on leptin and expression of leptin receptor transcripts in prepubertal dairy heifers. J Dairy Sci 90(8): 3742-3750, 2007.
32. Ozet A, Arpaci F, Yilmaz MI, Ayta H, Ozturk B, Komurcu S, Yavuz AA, Tezcan Y and Acikel C: Effects of tamoxifen on the serum leptin level in patients with breast cancer. Jpn J Clin Oncol 31(9): 424-427, 2001.
33. Chen HP, Fan J and Cui S: Detection and estrogen regulation of leptin receptor expression in rat dorsal root ganglion. Histochem Cell Biol 126(3): 363-369, 2006.
34. Coe JE, Ishak KG, Ward JM, and Ross MJ: Tamoxifen prevents induction of hepatic neoplasia by zeranol, an estrogenic food contaminant. Proc Natl Acad Sci USA 89(3): 1085-1089, 1992.
35. Liu S and Lin YC: Transformation of MCF-10A human breast epithelial cells by zeranol and estradiol-17beta. Breast J 10(6):514-521, 2004.
36. Takemura H, Shim JY, Sayama K, Tsubura A, Zhu BT, and Shimoi K: Characterization of the estrogenic activities of zearalenone and zeranol in vivo and in vitro. J Steroid Biochem Mol Biol 103(2): 170-177, 2007.
37. Narro LA, Thomas MG, Silver GA, Rozeboom KJ, and Keisler DH: Body composition, leptin, and the leptin receptor and their relationship to the growth hormone (GH) axis in growing wethers treated with zeranol. Dornest Anim Endocrinol 24(3): 243-255, 2003.
38. Yuri T, Tsukamoto R, Miki K, Uehara N, Matsuoka Y and Tsubura A: Biphasic effects of zeranol on the growth of estrogen receptor-positive human breast carcinoma cells. Oncol Rep 16(6): 1307-1312, 2006.
39. Liu S, Sugimoto Y, Sorio C, Tecchio C and Lin YC: Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTPgamma) in human breast cancer cell line MCF-7. Oncogene 23(6): 1256-1262, 2004.
40. Zhang M, Liu H, Guo R, Ling Y, Wu X, Li B, Roller PP, Wang S and Yang D: Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 66(1): 93-103, 2003.
41. Shidaifat F, Canatan H, Kulp SK, Sugimoto Y, Chang WY, Zhang Y, Brueggemeier RW, Somers WJ and Lin YC: Inhibition of human prostate cancer cells growth by gossypol is associated with stimulation of transforming growth factor-beta. Cancer Lett 107(1): 37-44, 1996.
42. Gilbert NE, O'Reilly JE, Chang CJ, Lin YC and Brueggemeier RW: Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci 57(1): 61-67, 1995.
43. Ye W, Chang HL, Wang LS, Huang YW, Shu S, Dowd MK, Wan PJ, Sugimoto Y and Lin YC: Modulation of multidrug-resistance gene expression in human breast cancer cells by (-)-gossypol-enriched cottonseed oil. Anticancer Res 27(1A): 107-116, 2007.
44. Roy PG and Thompson AM: Cyclin D1 and breast cancer. Breast 15(6): 718-727, 2006.